Intercept Pharmaceuticals
New York
About Intercept Pharmaceuticals
Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $970.0M
- Funding stage: M&A
- Last round: Post-IPO Debt (Jun 2016)
- Ticker: nasdaq:ICPT
- Website: interceptpharma.com
- Phone: +1 646 747 1000
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/intercept-pharmaceuticals-4511 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.